Inflammatory stimuli accelerate Sjogren's syndrome-like disease in (NZB x NZW)F1 mice
Inflammatory stimuli accelerate Sjogren's syndrome-like disease in (NZB x NZW)F1 mice
复制标题
DOI:
10.1002/art.23368
复制
发表时间:
2008-05-01
影响因子:
--
通讯作者:
Fu, Shu Man
中科院分区:
文献类型:
--
作者:
Deshmukh, Umesh S.;Ohyama, Yukiko;Fu, Shu Man
Objective. This study was undertaken to determine whether induction of systemic inflammation accelerates the development of Sjogren's syndrome (SS) in genetically susceptible mice.Methods. Female (NZB X NZW)F-1 mice were treated with either Freund's incomplete adjuvant (IFA) or phosphate buffered saline (PBS) at monthly intervals. Salivary gland function was monitored by measuring pilocarpine-induced saliva volume. Mice were killed at different time points and examined for sialadenitis and salivary gland-infiltrating cells. Sera were analyzed for autoantibodies to salivary gland antigens, nuclear antigens, and Ro60.Results. While IFA-treated mice had significantly decreased salivary secretion 7 weeks after the initial treatment, salivary secretion did not decrease in PBS-treated controls until 17 weeks. At 7 weeks, the severity of sialadenitis and the number of T and B cells infiltrating the salivary glands did not differ between the 2 groups. However, at this time point IFA-treated mice showed significantly higher frequencies of CD11c(low), B220+, Ly6C+, mouse PDCA-1+ dendritic cells (DCs) in the salivary glands. While levels of autoantibodies did not differ between the 2 groups at early time points, by late time points IFA-treated mice had higher levels. The gland dysfunction observed in IFA-treated mice at earlier time points did not correlate with the severity of sialadenitis or levels of autoantibodies. Instead, it was associated with increased frequency of plasmacytoid DCs in the gland.Conclusion. Our data suggest that generalized inflammatory stimuli can accelerate the development of SS-like disease in (NZB x NZW)F-1 mice, and that gland dysfunction in SS can develop prior to the generation of a robust adaptive autoimmune response.